S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?

Sage Therapeutics (SAGE) Stock Price, News & Analysis

$19.37
-0.60 (-3.00%)
(As of 03/18/2024 ET)
Today's Range
$18.96
$19.96
50-Day Range
$19.37
$26.95
52-Week Range
$16.51
$59.99
Volume
1.39 million shs
Average Volume
867,207 shs
Market Capitalization
$1.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.71

Sage Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.13 Rating Score
Upside/​Downside
115.3% Upside
$41.71 Price Target
Short Interest
Healthy
16.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.51
Upright™ Environmental Score
News Sentiment
0.60mentions of Sage Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.26) to ($4.52) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.84 out of 5 stars

Medical Sector

245th out of 946 stocks

Pharmaceutical Preparations Industry

107th out of 429 stocks

SAGE stock logo

About Sage Therapeutics Stock (NASDAQ:SAGE)

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

SAGE Stock Price History

SAGE Stock News Headlines

Sage Therapeutics Inc.
Central Bank Gold Heist In Progress
When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.
SAGE Jan 2025 30.000 put
Central Bank Gold Heist In Progress
When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.
SAGE Therapeutics, Inc. Q4 Loss decreases, beats estimates
Sage Therapeutics Q4 2023 Earnings Preview
Sage Therapeutics Inc
See More Headlines
Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/18/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SAGE
Employees
487
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$41.71
High Stock Price Target
$294.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+115.3%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
16 Analysts

Profitability

Net Income
$-541,490,000.00
Net Margins
-626.32%
Pretax Margin
-626.33%

Debt

Sales & Book Value

Annual Sales
$86.46 million
Book Value
$13.32 per share

Miscellaneous

Free Float
56,801,000
Market Cap
$1.16 billion
Optionable
Optionable
Beta
0.87
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Barry E. GreeneMr. Barry E. Greene (Age 61)
    President, CEO & Director
    Comp: $1.29M
  • Ms. Kimi E. Iguchi CPA (Age 62)
    CFO & Treasurer
    Comp: $665.37k
  • Ms. Anne Marie Cook Esq. (Age 62)
    Senior VP, General Counsel & Secretary
    Comp: $711.6k
  • Mr. Christopher Benecchi (Age 52)
    Chief Business Officer
    Comp: $703.76k
  • Dr. Laura Gault M.D.
    Ph.D., Chief Medical Officer
  • Mr. Matt Lasmanis
    Chief Technology & Innovation Officer
  • Mr. Mike Quirk
    Chief Scientific Officer
  • Ashley Kaplowitz
    Director of Investor Relations
  • Ms. Erin E. Lanciani (Age 55)
    Chief People & Experience Officer
  • Dr. Amy Schacterle Ph.D.
    Senior Vice President of R&D Strategy and Business Management

SAGE Stock Analysis - Frequently Asked Questions

Should I buy or sell Sage Therapeutics stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last twelve months. There are currently 14 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings
or view top-rated stocks.

What is Sage Therapeutics' stock price target for 2024?

16 brokerages have issued 12-month target prices for Sage Therapeutics' shares. Their SAGE share price targets range from $20.00 to $294.00. On average, they predict the company's share price to reach $41.71 in the next year. This suggests a possible upside of 115.3% from the stock's current price.
View analysts price targets for SAGE
or view top-rated stocks among Wall Street analysts.

How have SAGE shares performed in 2024?

Sage Therapeutics' stock was trading at $21.67 at the beginning of the year. Since then, SAGE shares have decreased by 10.6% and is now trading at $19.37.
View the best growth stocks for 2024 here
.

When is Sage Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our SAGE earnings forecast
.

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) posted its quarterly earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($1.28) by $0.73. The biopharmaceutical company earned $77.97 million during the quarter, compared to analyst estimates of $60.15 million. Sage Therapeutics had a negative net margin of 626.32% and a negative trailing twelve-month return on equity of 54.41%. The firm's quarterly revenue was up 2621.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.47) EPS.

What ETFs hold Sage Therapeutics' stock?
What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (10.08%), Vanguard Group Inc. (8.86%), Vanguard Group Inc. (8.85%), RTW Investments LP (8.66%), Palo Alto Investors LP (1.65%) and Dimensional Fund Advisors LP (1.61%). Insiders that own company stock include Barry E Greene, Barry E Greene, Elizabeth Barrett, George Golumbeski, James M Frates and Jeffrey M Jonas.
View institutional ownership trends
.

How do I buy shares of Sage Therapeutics?

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SAGE) was last updated on 3/19/2024 by MarketBeat.com Staff

From Our Partners